Latest Ratios: P/E Ratio -3.0x · EV/EBITDA N/A · ROE -10245.9%. (1999–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $96M | $83M | $70M | $91M | $95M | $74M | $96M | $105M | $29M | $76M | $25M |
| Enterprise Value | $92M | $77M | $55M | $57M | $83M | $34M | $65M | $92M | $15M | $64M | $13M |
| P/E Ratio → | -2.96 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 11.68 | 3.31 | 3.57 | 2.06 | 3.88 | — | 4.68 | 9.12 | 2.36 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -10245.9% | -10245.9% | -189.1% | -76.1% | -60.9% | -69.0% | -136.2% | -1496.6% | -235.3% | -164.6% | -85.6% |
| ROA | -258.0% | -258.0% | -107.5% | -54.0% | -45.8% | -52.3% | -62.1% | -263.9% | -103.2% | -94.9% | -71.9% |
| ROIC | — | — | — | -453.4% | -289.9% | — | — | — | — | — | — |
| ROCE | -507.5% | -507.5% | -145.5% | -73.7% | -54.0% | -55.9% | -98.8% | -219.7% | -133.5% | -132.2% | -86.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.18 | 0.02 | 0.01 | 0.02 | 0.02 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -2.49 | -1.25 | -0.43 | -1.12 | -1.25 | — | -2.21 | -1.43 | -1.13 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($7M) exceeds total debt ($772509)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | 1.12 | 2.82 | 9.01 | 9.05 | 16.69 | 12.45 | 1.47 | 5.13 | 3.41 | 3.55 |
| Quick Ratio | 1.12 | 1.12 | 2.82 | 9.01 | 9.05 | 16.69 | 12.45 | 1.47 | 5.13 | 3.41 | 3.55 |
| Cash Ratio | 0.85 | 0.85 | 2.38 | 8.24 | 8.15 | 15.34 | 11.52 | 1.10 | 4.87 | 2.26 | 3.47 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $96M | $76M | $68M | $58M | $54M | $40M | $22M | $16M | $14M | $13M |
Imminent liquidity depletion risk
According to recent quarterly filings, the company's current ratio has compressed significantly from 9.01 in 2023Q4 to 1.38 in 2026Q1, signaling a rapid depletion of the liquid assets necessary to sustain ongoing clinical trial operations without immediate external capital injections or partnership-driven milestone payments.
The sharp decline in the current ratio suggests that the company's ability to cover short-term obligations is becoming increasingly precarious. Investors should monitor the narrowing gap between cash reserves and accrued liabilities, as the current liquidity profile leaves little room for operational delays or unexpected clinical trial cost overruns.
Based on reported financial statements, the company's debt-to-equity ratio has experienced extreme volatility, peaking at 7.26 in 2025Q3, which reflects the compounding impact of persistent net losses and the erosion of shareholder equity as the firm continues to fund its development-stage pipeline through dilutive financing.
The shift toward negative equity suggests that the company's capital structure is under significant pressure, rendering traditional leverage metrics less meaningful. This trend warrants further investigation into the long-term sustainability of the current financing model, particularly as the firm lacks the operating cash flow to service debt obligations.
As reported in historical financial data, the company's return on assets has consistently remained in negative territory, reaching -163.8% in 2026Q1, which underscores the fundamental challenge of generating returns on invested capital while the firm remains in a pre-revenue, high-burn clinical development phase.
The persistent negative ROA indicates that capital is being consumed at a rate that far outpaces the progress of clinical milestones. This trend suggests that the company is currently destroying shareholder value rather than compounding it, a reality that will likely persist until the firm can demonstrate a clear path to commercialization.
Based on an analysis of the company's financial profile, the price-to-earnings ratio is the most commonly misapplied metric, as it obscures the reality that the firm is a pre-revenue entity where earnings are non-existent and losses are driven by necessary, yet non-recurring, clinical development expenditures.
Investors should instead focus on cash-to-milestone ratios or the clinical trial burn rate, as these metrics provide a more accurate assessment of the company's operational runway. Relying on P/E multiples in this context is misleading and fails to capture the binary nature of the firm's underlying biotechnology assets.
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ONCY stock.
Oncolytics Biotech Inc.'s current P/E ratio is -3.0x. This places it at the 50th percentile of its historical range.
Oncolytics Biotech Inc.'s return on equity (ROE) is -10245.9%. The historical average is -84.1%.
Based on historical data, Oncolytics Biotech Inc. is trading at a P/E of -3.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.